semaglutide
Ozempic · Wegovy · Rybelsus
1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )
Mechanism. 12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
FDA requires a boxed warning on this label. See full prescribing information.
What stands out in the reports.
ROR = reporting odds ratio (log-schaal). Een waarde boven 1 betekent dat het symptoom vaker wordt gemeld voor dit product dan voor alle andere producten samen. Dit meet hoeveel het opvalt in meldingen — geen causaliteit, geen risico.
Semaglutid zeigt häufig gemeldete Nebenwirkungen wie verzögerte Magenentleerung (ROR 92.1), Darmverschluss (ROR 7.7) und Pankreatitis (ROR 7.5). Die verzögerte Magenentleerung ist logisch, da Semaglutid die Magenentleerung verlangsamt, um das Sättigungsgefühl zu fördern. Auch Verstopfung (ROR 6.3) und Blähungen (ROR 5.0) sind im Kontext der gastrointestinalen Wirkung plausibel. Beachten Sie, dass "häufig gemeldet" nicht "häufig verursacht" bedeutet. Dies ersetzt keinen medizinischen Rat.
Dit vervangt geen medisch advies.
No signals currently mapped to the label.
Report volume per quarter.
| Date | Class | Reason | Firm |
|---|---|---|---|
| Mar 15, 2021 | II | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | Cardinal Health Inc. |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm. Source: openFDA enforcement.